<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840708</url>
  </required_header>
  <id_info>
    <org_study_id>NTU</org_study_id>
    <nct_id>NCT02840708</nct_id>
  </id_info>
  <brief_title>SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study</brief_title>
  <official_title>SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niigata University Medical &amp; Dental Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niigata University Medical &amp; Dental Hospital</source>
  <brief_summary>
    <textblock>
      Objective: Evaluate Pharmacokinetics and determine the safety of GM-CSF single dose
      inhalation.

      Study Design: Pharmacokinetic open study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum level of Sargramostim</measure>
    <time_frame>0.5,1,2,4,8,12 and 24 hours after inhalation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pulmonary Alveolar Proteinosis, Autoimmune</condition>
  <arm_group>
    <arm_group_label>125mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1401 125mcg single inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1401 250mcg single inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1401 500mcg single inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <arm_group_label>125mcg</arm_group_label>
    <arm_group_label>250mcg</arm_group_label>
    <arm_group_label>500mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects judged to be appropriate for the study by the attending physician

          2. can provide signed informed consent.

             aPAP patient must meet the following

          3. aPAP patient aged over 20 and below 80 years old (as of the date of registration)

          4. aPAP severity is mild or moderate. (not severe)

             Healthy volunteer must meet the following

          5. Japanese healthy male subject aged over 20 and below 45 years old (as of the date of
             registration).

          6. BMI (Body mass index) is between 18 and 25.

        Exclusion Criteria:

          1. WBC of 12,000/mcl or more

          2. Fever of 38 degree celsius or more

          3. History of malignant disease within recent 5 years (not applied to the treated cases
             of local basal cell carcinoma)

          4. Complication of severe cardiovascular diseases including congestive heart failure,
             angina pectoris, hemorrhagic tendency, etc.

          5. Complication of respiratory diseases such as pulmonary infectious disease(incl.
             pulmonary tuberculosis), interstitial pneumonitis, lung fibrosis or bronchiectasis, in
             which the evaluations of safety of GM-CSF therapy are considered to be difficult.

          6. History or complication of infectious diseases which require systemic administration
             of antibiotics, antifungal or antiviral agents within recent 2 weeks.

          7. liver dysfunction

          8. renal dysfunction

          9. Previous experience of severe and unexplained adverse events during aerosol delivery
             of any kind of medicinal product

         10. Positive for HIV-Ab, HBs-Ag, HCV-Ab, STS or TPHA

         11. allergic to GM-CSF.

         12. addicted to illegal drugs

         13. Participation to other clinical trials within 12 weeks before registration.

         14. smoking within 5 years

         15. cannot follow the procedure defined in this protocol

             aPAP patient must exclude the following

         16. Pregnant or possibly pregnant women, lactating women, and women who desire to become
             pregnant during the study period

         17. Patients who have been treated with whole-lung lavage, repeated segmental-lung lavage,
             GM-CSF or rituximab within 6 months before the start of the study.

         18. taking other inhalation.

             Healthy volunteer must exclude the following

         19. taking any medicines (incl. OTC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Niigata University Med &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

